Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Topp

Showing results (111-120 of 308) with videos related to

Pageof 31
Sort By:
Cancer Journal (Sudbury, Mass.)|June 30, 2000
Immunotherapy of human viral and malignant diseases with genetically modified T-cell clonesS R Riddell, E H Warren, M A Gavin, et al.
Brain Research. Molecular Brain Research|September 5, 2001
Characterisation of gene expression changes following permanent MCAO in the rat using subtractive hybridisationS Bates, S J Read, D C Harrison, et al.
Blood|February 3, 2009
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)Stefan Knop, Christian Gerecke, Peter Liebisch, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2019
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell TransplantationAnthony S Stein, Hagop Kantarjian, Nicola Gökbuget, et al.
Cancer|November 3, 2020
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomabMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Cancer Research|November 17, 2006
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cellsClaudia M Kowolik, Max S Topp, Sergio Gonzalez, et al.
Journal of the American College of Surgeons|June 8, 1999
Systemic effects and side effects of interstitial techniques used in liver tissueC Brunken, S Topp, C Tesch, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Blood Cancer Journal|July 30, 2025
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
Blood Cancer Journal|November 1, 2025
Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
Pageof 31

Showing results (111-120 of 308) with videos related to

Sort By:
Pageof 31
Cancer Journal (Sudbury, Mass.)|June 30, 2000
Immunotherapy of human viral and malignant diseases with genetically modified T-cell clonesS R Riddell, E H Warren, M A Gavin, et al.
Brain Research. Molecular Brain Research|September 5, 2001
Characterisation of gene expression changes following permanent MCAO in the rat using subtractive hybridisationS Bates, S J Read, D C Harrison, et al.
Blood|February 3, 2009
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)Stefan Knop, Christian Gerecke, Peter Liebisch, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2019
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell TransplantationAnthony S Stein, Hagop Kantarjian, Nicola Gökbuget, et al.
Cancer|November 3, 2020
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomabMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Cancer Research|November 17, 2006
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cellsClaudia M Kowolik, Max S Topp, Sergio Gonzalez, et al.
Journal of the American College of Surgeons|June 8, 1999
Systemic effects and side effects of interstitial techniques used in liver tissueC Brunken, S Topp, C Tesch, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Blood Cancer Journal|July 30, 2025
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
Blood Cancer Journal|November 1, 2025
Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
Pageof 31